California sober

Last updated

California Sober (or California Sobriety) is a recovery model that incorporates the use of psychedelic therapy, along with meditation and exercise, with the intent of abstaining from more harmful and addictive substances. [1] [2] [3] [4] The difference between the California Sober and traditional recovery systems, such as Narcotics Anonymous, is that it doesn't require Asceticism, allowing the practitioner to use substances with little to no potential for addiction in such a way that those substances are said to aid in the recovery process.

Contents

The method has recently gained popularity among people looking for alternatives to the Twelve-step programs, partially due to an article in Vice magazine, [5] songs by recording artists Demi Lovato [6] and Billy Strings [7] (featuring Willie Nelson), and a book on the subject by author W. E. Simmons. [8]

History

The term California Sober originated in the US state of California as a way of referring to a method of recovery from alcohol and other substances by using marijuana and classic psychedelics as an immediate deterrent from alcohol and other harmful addictive substances. The method also uses classic psychedelics as a long-term deterrent from the same. Although the term has been used for decades to describe a method of recovery that utilizes classic psychedelics, such as LSD, mescaline, Psilocybin mushrooms, and cannabis to aid in recovery from harmful and addictive substances, online use of the term only dates back to 2016. [9]

The California Sober Method

The California Sober method is described as using classic psychedelics, along with talk therapy, meditation, exercise, yoga, and breathwork, to overcome addiction to harmful substances such as Alcoholic beverages, street drugs, and pharmaceuticals. The California Sober method stresses the need to use these substances with the express intent of recovering from Alcoholism, Addiction, and many other Mental disorders. [10]

Methods include California Sober Remediation Therapy (CSRT), which includes Cannabis Remediation Therapy (CRT), Psychedelic Remediation Therapy (PRT), and Meditative Remediation Therapy (MRT). [11] After the initial remediation is complete, the California Sober method relies on psychedelic therapy at intervals that can be anywhere from 1 to 12 months apart, depending on the addict's response to treatment, shortening intervals until they are no longer necessary. [12] [13]

The California Sober method also includes Self-help steps, including a specialized form of meditation, three questions, nine goals, and 13 paths that work as therapy to bring the individual to a state of mind that supports recovery. [14]

The Studies

Both the novel and historical studies show that classic psychedelics may be useful in treating Alcohol Use Disorder, [15] [16] [17] [18] [19] Substance use disorder, Opioid use disorder, [20] [21] Cocaine use disorder [22] and Nicotine Addiction. [23] [24] California Sober methods have also been shown to be beneficial in treating depression, Obsessive–compulsive disorder, Post-traumatic stress disorder, and a host of other mental ailments, as shown by the following studies.

LSD Studies

The study of LSD's medicinal value was halted by the Nixon administration's anti-counterculture movement, also known as the War on drugs, in the late 1960s.  Its Schedule I controlled substance designation directly contradicted decades of scientific and medical research.  By the time LDS was outlawed, dozens of studies had already been conducted between LSD's creation by Albert Hofmann and its prohibition by the Nixon administration.  From ending addictive behaviors and lessening the chance of relapse to relief from anxiety and depression, study after study suggested that LSD could re-shape the mind in a way that had never been seen before, or since.

Scientists have recently conducted a study to examine the combined effect of LSD and alcohol misuse. The results of the study were published in the Journal of Psychopharmacology. In a retrospective analysis, researchers found that out of 536 participants, 59% of those who received LSD reported lower levels of alcohol misuse. The promising results were observed during follow-up visits at two and three months and again at six months. However, no significant results were observed during the 12-month follow-up, which suggests that recurring treatment may be necessary. [25]

In a 2020 study titled Therapeutic Use of LSD in Psychiatry, published in Frontiers in Psychiatry, researchers noted that "...LSD is revealed as a potential therapeutic agent in psychiatry; the evidence to date is strongest for the use of LSD in the treatment of alcoholism."  In addition, the study's authors commented on the safety of psychedelics, writing that "as a recreational drug, LSD does not entail physical dependence as withdrawal syndrome, as do most of these substances (opioids, cocaine, cannabis, and methamphetamine).  Its frequent or long-term use can lead to tolerance, and after a single dose, emotional, physical, and mental stability is quickly recovered.  Likewise, classical hallucinogens, in general, and LSD, in particular, exhibit very low physiological toxicity, even at very high doses, without any evidence of organic damage or neuropsychological deficits associated with their use. Their safety has recently led to considering LSD as one of the safest psychoactive recreational substances." [26]

Although retrospective analyses offer much insight, the studies conducted during the 1960s are equally noteworthy. Many doctors and scientists were amazed at the remarkable success that LSD treatment provided. Critics, however, argue that it is impossible to conduct a blind study since it was apparent to both the patient and doctor who received the LSD and who received the placebo.  As an example of the rates of addiction recovery that they were finding, the following results were from various studies of the time.

In a review of studies published in the Canadian Psychiatric Association Journal Vol. 14, No.1, 1969, author C.G. Costello wrote that an unpublished report by the Saskatchewan Bureau on Alcoholism indicated that 69 (47.6%) of 145 alcoholics improved after LSD treatment.  The study period was from 1957 to 1962, and the intervals between treatment and follow-up varied from two months to five years, most cases having had the last treatment between two and four years before their follow-up. 50 of the 69 improved cases were "totally dry," meaning they had not had any alcohol since their treatment.

Of the remaining 19, "their relapses are becoming fewer and of shorter duration, e.g., one day of intoxication compared to previous bout pattern of one week; gainfully employed as compared to former chronic unemployment."  He says that improvement for the six studies "average from 50% to 93% with a mean of 75%. This would suggest that LSD therapy is indeed a worthwhile method of treatment..." [27]   Considering 12-step programs average a less than 10% recovery rate for all that make the attempt, an average of 75% of patients improving drastically is unheard of.

Another study, from June 1963, had impressive results with the most hard-core addicts that could be found.  Most of the patients treated had been referred by another Alcoholic Counselling Center whose policy had been to refer their most severe or chronic cases to the Saskatchewan Hospital.  As a result, those treated were all patients who would be considered to have a severe addiction by all ordinary means of evaluation.  87% had tried and failed with Alcoholics Anonymous at least once, and 57% had received some psychiatric treatment at least once prior. Their age ranged from 24 to 65, and the average age was 39.3.

Of 70 patients receiving the complete treatment, including LSD therapy, and followed up between six and 18 months after discharge, 39 (56%), "had remained dry continuously since discharge or had been dry apart from a short "testing" bout of drinking immediately after discharge."  Out of the 55 patients in the control group who received individual psychiatric treatment alone, only 8 (14%) remained sober. "A chi-square test showed that significantly more of the alcoholics treated with LSD were dry or improved at the time of follow-up than patients receiving group therapy alone or of the controls." [28]   In this group where 87% had tried and failed with Alcoholics Anonymous at least once, we have 56% of the group totally sober at 6 and 18 months after LSD therapy. Where 12-step groups fail, California Sober methods prosper as an alternative.

Dr. Harold A. Abramson, M.D. edited the minutes from the Second International Conference on the Use of LSD in Psychotherapy and Alcoholism, which took place in May 1965. During the conference, a group of psychiatry investigators gathered in Amityville, New York, to discuss their findings and research in the field.  According to his notes, "the purpose of the meeting was to exchange information and discuss problems regarding the use of a remarkable drug that has been a focus of research in psychiatry for more than twenty years." That substance was LSD-25, commonly known as LSD.

At the conference of nearly 50 doctors who had tested LSD on patients, all were aligned by one commonality.  "The scientific literature . . . is singularly affirmative.  Every worker who studied LSD's use for treating alcoholism is in unusual agreement."  "Their uncommon consensus was that they had all found LSD to be effective."  On the subject of relapse, Doctor Abram Hoffer remarked, "Had they been given 200 mcg or more (of LSD), with a therapeutic objective, in a therapeutic setting, by therapists interested in the therapeutic experience, and had they used the community resources, including A.A., perhaps at three-and-one-half years about fifty percent or more of their subjects would have been sober." [29]

The work done by Betty Eisner, with Bill W. and others, was remarkable and way ahead of its time.  She was so excited about her discoveries that she wrote of her work to her role model, founder of analytic psychology and Swiss psychiatrist, Carl Jung.  Betty couldn't wait to tell Mr. Jung of her success in using the LSD treatment with her patients.  "For the past six to nine months," she wrote in a letter dated August 2, 1957, "I have been engaged in an absorbingly interesting pilot study of the therapeutic aspects of lysergic acid (LSD-25). ...LSD unlocks the door to an individual's unconscious. ... {there} are levels of the unconscious available which have been described heretofore only by the mystics and poets. ... when taken under proper circumstances and with the proper preparation and dosages, {LSD} accomplishes in a handful of sessions the process of discovering one's place and function in life and the universe which you call individuation."

One month later, on September 3 of the same year, she sent another letter explaining more of her research.  "It appears that the individual man experience what is most necessary {through the use of LSD} -- and to the amount he can take," she said of her weekly sessions with patients taking increasing doses each week.  "We have also observed that at times it is possible to slip past the areas of difficulty of the Ego... Woe to the person who does not do his utmost to integrate the insights he gains under LSD into his every-day life!"  She ends by saying, "I have never experienced anything which has helped me more than LSD in the process of attempting to free myself from the limitations, conditionings, and ego-centricities-- on the many levels-- which prevent us from being the loving individuals which we were all created to be."

From the many studies on its benefits toward reducing addiction to renowned author, researcher, and psychologist Betty Eisner's work (among many others) in psychotherapy, LSD has been proven to treat many debilitating issues, from depression to alcoholism and more.  Had it not been for the misguided Controlled Substance Act, countless studies could have been performed that would show its benefits in many other areas of psychiatry, similar to that of Psilocybe cubensis mushrooms, peyote, mescaline, and even Cannabis.  Though more studies will be done in the future, as its benefits are too apparent to ignore, one fact remains.  LSD has the ability to treat alcoholism and other addictions.

In one of the first LSD studies since the 1960s, researchers found that LSD also significantly decreased state and trait anxiety in terminal patients (fear of death and related consequences) at two months and sustained that reduction for 12 months. [30]   In other words, terminally ill patients facing the end of their lives found relief from their worries, both mentally and spiritually, through the use of LSD-25. This study confirmed what the studies of the 1950s and 60s had shown.  LSD is a remarkable psychiatric substance that can have lasting benefits across the spectrum of psychiatric issues, in addition to its remarkable rate of success in treating addiction.

Psilocybin Mushroom Studies

Since the psychedelic re-awakening of the 1990s, studies have shown that Psilocybin, the main ingredient in Magic mushrooms, is effective in many of the psychological disorders it is tested for. When administered to subjects with obsessive-compulsive disorder, all patients showed improvements within 24 hours of treatment, yielding a 23%-100% decrease in the Yale-Brown Obsessive Compulsive Scale score. [31]   For Anxiety and Depression in patients with advanced-stage cancer and reactive anxiety, Psilocybin significantly reduced anxiety one month after treatment, and depression was significantly lower at six months. [32]   When used for quitting smoking, 80% of the trial participants were abstinent at a 6-month follow-up. [33] [34]  Significant decreases in drinking behavior for up to 9 months were shown when Psilocybin was used to treat Alcohol Use Disorder.  In Major Depressive Disorder, the Mushrooms significantly decreased depressive symptoms for up to 6 months. [35]   Anxiety and depression related to life-threatening cancer was significantly decreased at 7 weeks and sustained for 6.5 months [36] with another study duplicating the results showing significant decreases in anxiety and depression at 5 weeks with effects sustained for 6 months. [37]

A Jama Psychiatric article laid out the results of the largest-ever trial of psilocybin, the active alkaloid in magic mushrooms, in the treatment of alcoholism.  About half of the participants, all of whom were alcohol-dependent for an average of 14 years, were given psilocybin, while the other half were given an antihistamine as a placebo.  Both groups were also given psychotherapy.  The psilocybin group reduced their heavy drinking days by 83% (compared to about 50% in those who received the placebo), and the number and frequency of drinking days and drinks they consumed were also significantly lower.  Eight months later, close to half of the Psilocybin group had stopped drinking altogether. [38]

Other studies found naturalistic psychedelic use to be independently associated with significantly reduced odds of subsequent daily illicit opioid use among a community-based sample of people who used substances.  "These findings suggest that psychedelic use may be associated with reductions in substance use, including illicit opioid use, [39] and that psilocybin use was associated with a 30% reduction in the odds of Opiate Use Disorder." [40]

Peyote (Mescaline) Studies

Studies by the Native American Church that have been conducted from 1977 to the present suggest that the use of peyote therapy significantly reduces the alcohol consumption in its members and that these members fare better than those who participate in Alcoholics Anonymous. [41]   Because Peyote is a controlled substance (for anyone who is not a member of the Native American Church), studies are mostly limited to the observations of the Church and its members.  However, it became apparent to the observers of the church's studies that Peyote, like every other classic psychedelic, has a significant benefit in the reduction of alcohol in those suffering from alcoholism.

While Peyote and other psychedelic cacti are less studied than other psychedelics like Magic Mushrooms, studies have been conducted in recent years showing that Peyote lowered the odds of Cocaine Use Disorder, reducing the odds of CUD by over 50%, [42] and that peyote use is associated with lowered odds of nicotine dependence. [43]   From these studies, which mimic those of LSD, Psilocybe, and other hallucinogens, we can surmise that Peyote is on par with its cousins when used to treat other addictions.  One can also safely assume that San Pedro would have similar effects because it contains the same active ingredient in smaller quantities.

Cannabis Studies

Studies show that on days when alcoholics ingested cannabis, they consumed 29% fewer drinks and were twice less likely to binge drink. [44]  Both regular users and those who used only to not drink had similar results regarding daily consumption. The results show that when addicts use cannabis to abstain from other substances, they reduce their consumption.

In another study published in the International Journal of Drug Policy, 973 patients were questioned about their alcohol use before and after receiving medical marijuana treatment. 44% reported drinking less frequently every month, and 34% drank fewer drinks per week. In addition, 8% said they drank no alcohol in the last month of the survey. [45]  These studies show that cannabis can be used to lessen the desire for other substances.

Because cannabis is safer than alcohol and other harmful substances, its use as a replacement and/or as a deterrent is more than justified. However, unlike the classic psychedelics mentioned previously, a small percentage of the population can develop cannabis use disorder (CUD). Some studies have suggested that 9% of people who use cannabis will develop CUD, [46] [47] with those numbers rising to about 17% in those who start using in their teens. [48] [49]

Meditation studies

Groundbreaking research conducted by the University of Utah and published on October 12, 2022, in the journal Science Advances has shown that Mindfulness Meditation, when combined with therapy, can significantly reduce the usage of opioids in long-term users. The study reveals that Mindfulness Meditation alters the users' state of mind and increases the theta waves, which are linked with REM sleep. The low theta waves are associated with the inability to concentrate and wandering thoughts that are often negative. They also lead to a lack of self-control, and the brain slips into the DMN or default mode network. The Mindfulness-Oriented Recovery Enhancement (MORE) treatment, developed by Professor Eric Garland, has been successful in treating addiction. The study involved the most significant neuroscience research on Mindful Meditation, and the MORE treatment more than doubled frontal midline theta brain activity.

In simple terms, the default mode is when individuals perform actions without consciously thinking about them. High theta activity, on the other hand, quiets the mind and allows individuals to focus more on their activity. High theta waves can be compared to being in the zone while playing a game or sport. In contrast, default mode is when an individual worries about something and opens a beer or drinks a glass of wine without even realizing it.

The randomized clinical trial involved 250 adults who suffered from both chronic pain and opioid misuse. The participants were divided into two groups: the group that underwent the MORE treatment and the control group. The results showed that 45% of those who completed the MORE treatment were no longer misusing opioids nine months later, compared to only 24% of patients in the control group. The trial participants suffered from chronic pain and could not quit opioids altogether. However, the MORE group learned to control their addiction while still using opioids for pain management. They reduced their normal dosage, experienced fewer cravings, and less emotional distress. The trial was published in the April 2022 issue of JAMA Internal Medicine. [50]

Previous research has indicated that practicing meditation can increase the chances of an individual refraining from alcohol and other substances. A study conducted in 2018 and published in the Journal of Substance Abuse Treatment revealed that individuals who practiced Transcendental Meditation (TM) were more than twice as likely to remain abstinent from alcohol as compared to the control group (25% versus 59%). Furthermore, while half of the control group returned to heavy drinking, none of the TM group members did. [51]

Breathwork studies

Breathing is one of the few things we can do consciously and unconsciously.  Controlling your breath can provide a link between both realms of the mind and also help regulate emotions.  A breathing method called Cyclic breathing can quickly regress composure in stressful situations or elevate your mood. In this simplified method of meditation, all you need is five minutes to promote more positive and fewer negative feelings, relieve anxiety, and lower your heart rate and blood pressure while producing some of those feel-good hormones that we all love. [52]

Exercise and Yoga studies

Engaging in physical activity, especially cardiovascular exercise that increases heart rate, has been proven effective in treating addiction. This is likely because exercise boosts dopamine levels in the brain, stimulating the same reward center that alcohol and other mind-altering substances trigger. When we exercise, our brain produces more of those feel-good hormones it craves, thus reducing the need for external substances to supplement them. Additionally, exercise can minimize cravings, lower anxiety levels, and increase dopamine in the brain.

According to one study by Frontiers in Psychiatry, published on the National Institute of Health website, "...exercise was shown to influence many of the same signaling molecules and neuroanatomical structures that mediate the positive reinforcing effects of drugs." [53]   In a separate study, rats were presented with a dispenser containing different substances, including morphine and amphetamines. The rats that utilized an exercise wheel hit the dispenser far less often than those that did not exercise at all. This study has been replicated multiple times, consistently yielding similar results. [54] [55]

Scientific studies have revealed that practicing Yoga improves physical fitness and increases the level of gamma-aminobutyric acid (GABA) in the brain. GABA is a chemical that plays a crucial role in managing anxiety and stress. In addition, the intense breathing patterns used in Yoga practice release endorphins, the body's natural pleasure-inducing hormones. The word endorphin combines two words - endogenous (meaning from within) and morphine. Therefore, it is reasonable to suggest that the body's natural surge of endorphins triggered by Yoga and other physical activities would help control cravings by providing the addict with a natural high. [56]

Demi Lovato released a song named California Sober on her album Dancing with the Devil... the Art of Starting Over and also speaks about being California Sober in her docuseries Demi Lovato: Dancing with the Devil. Billy Strings released a single named California Sober featuring Willie Nelson. [57] There is also a short movie called California Sober [58]

Related Research Articles

<span class="mw-page-title-main">Alcoholism</span> Problematic excessive alcohol consumption

Alcoholism is the continued drinking of alcohol despite it causing problems. Some definitions require evidence of dependence and withdrawal. Problematic use of alcohol has been mentioned in the earliest historical records, the World Health Organization (WHO) estimated there were 283 million people with alcohol use disorders worldwide as of 2016. The term alcoholism was first coined in 1852, but alcoholism and alcoholic are stigmatizing and discourage seeking treatment, so clinical diagnostic terms such as alcohol use disorder or alcohol dependence are used instead.

<span class="mw-page-title-main">LSD</span> Hallucinogenic drug

Lysergic acid diethylamide, commonly known as LSD, and known colloquially as acid or lucy, is a potent psychedelic drug. Effects typically include intensified thoughts, emotions, and sensory perception. At sufficiently high dosages, LSD manifests primarily mental, visual, and auditory hallucinations. Dilated pupils, increased blood pressure, and increased body temperature are typical.

<span class="mw-page-title-main">Recreational drug use</span> Use of drugs with the primary intention to alter the state of consciousness

Recreational drug use is the use of one or more psychoactive drugs to induce an altered state of consciousness, either for pleasure or for some other casual purpose or pastime. When a psychoactive drug enters the user's body, it induces an intoxicating effect. Recreational drugs are commonly divided into three categories: depressants, stimulants, and hallucinogens.

<span class="mw-page-title-main">Psychedelic drug</span> Hallucinogenic class of psychoactive drug

Psychedelics are a subclass of hallucinogenic drugs whose primary effect is to trigger non-ordinary mental states and an apparent expansion of consciousness. Also referred to as classic hallucinogens or serotonergic hallucinogens, the term psychedelic is sometimes used more broadly to include various types of hallucinogens, such as those which are atypical or adjacent to psychedelia like salvia and MDMA, respectively.

Drug rehabilitation is the process of medical or psychotherapeutic treatment for dependency on psychoactive substances such as alcohol, prescription drugs, and street drugs such as cannabis, cocaine, heroin or amphetamines. The general intent is to enable the patient to confront substance dependence, if present, and stop substance misuse to avoid the psychological, legal, financial, social, and physical consequences that can be caused.

Psychedelic therapy refers to the proposed use of psychedelic drugs, such as psilocybin, MDMA, LSD, and ayahuasca, to treat mental disorders. As of 2021, psychedelic drugs are controlled substances in most countries and psychedelic therapy is not legally available outside clinical trials, with some exceptions.

The Multidisciplinary Association for Psychedelic Studies (MAPS) is an American nonprofit organization working to raise awareness and understanding of psychedelic substances. MAPS was founded in 1986 by Rick Doblin and is now based in San Jose, California.

Substance dependence, also known as drug dependence, is a biopsychological situation whereby an individual's functionality is dependent on the necessitated re-consumption of a psychoactive substance because of an adaptive state that has developed within the individual from psychoactive substance consumption that results in the experience of withdrawal and that necessitates the re-consumption of the drug. A drug addiction, a distinct concept from substance dependence, is defined as compulsive, out-of-control drug use, despite negative consequences. An addictive drug is a drug which is both rewarding and reinforcing. ΔFosB, a gene transcription factor, is now known to be a critical component and common factor in the development of virtually all forms of behavioral and drug addictions, but not dependence.

<span class="mw-page-title-main">Hallucinogen persisting perception disorder</span> Medical condition

Hallucinogen persisting perception disorder (HPPD) is a non-psychotic disorder in which a person experiences apparent lasting or persistent visual hallucinations or perceptual distortions after using drugs, including but not limited to psychedelics, dissociatives, entactogens, tetrahydrocannabinol (THC), and SSRIs. Despite being designated as a hallucinogen-specific disorder, the specific contributory role of psychedelic drugs is unknown.

The Beckley Foundation is a UK-based think tank and UN-accredited NGO, dedicated to activating global drug policy reform and initiating scientific research into psychoactive substances. The foundation is a charitable trust which collaborates with leading scientific and political institutions worldwide to design and develop research and global policy initiatives. It also investigates consciousness and its modulation from a multidisciplinary perspective, working in collaboration with scientists. The foundation is based at Beckley Park near Oxford, United Kingdom. It was founded in 1998, and is directed by Amanda Feilding, Countess of Wemyss.

Post-acute withdrawal syndrome (PAWS) is a hypothesized set of persistent impairments that occur after withdrawal from alcohol, opiates, benzodiazepines, antidepressants, and other substances. Infants born to mothers who used substances of dependence during pregnancy may also experience a PAWS. While PAWS has been frequently reported by those withdrawing from opiate and alcohol dependence, the research has limitations. Protracted benzodiazepine withdrawal has been observed to occur in some individuals prescribed benzodiazepines.

<span class="mw-page-title-main">Psychoactive drug</span> Chemical substance that alters nervous system function

A psychoactive drug, psychopharmaceutical, psychoactive agent, or psychotropic drug is a chemical substance that changes the function of the nervous system and results in alterations of perception, mood, cognition, and behavior. These substances may be used medically, recreationally, for spiritual reasons, or for research. Some categories of psychoactive drugs may be prescribed by physicians and other healthcare practitioners because of their therapeutic value.

About 1 in 7 Americans suffer from active addiction to a particular substance. Addiction can cause physical, psychological, and emotional harm to those who are affected by it. The American Society of Addiction Medicine defines addiction as "a treatable, chronic medical disease involving complex interactions among brain circuits, genetics, the environment, and an individual's life experiences. People with addiction use substances or engage in behaviors that become compulsive and often continue despite harmful consequences." In the world of psychology and medicine, there are two models that are commonly used in understanding the psychology behind addiction itself. One model is referred to as the disease model of addiction. The disease model suggests that addiction is a diagnosable disease similar to cancer or diabetes. This model attributes addiction to a chemical imbalance in an individual's brain that could be caused by genetics or environmental factors. The second model is the choice model of addiction, which holds that addiction is a result of voluntary actions rather than some dysfunction of the brain. Through this model, addiction is viewed as a choice and is studied through components of the brain such as reward, stress, and memory. Substance addictions relate to drugs, alcohol, and smoking. Process addictions relate to non-substance-related behaviors such as gambling, spending money, sexual activity, gaming, spending time on the internet, and eating.

<span class="mw-page-title-main">Harris Isbell</span> American pharmacologist

Harris Isbell was an American pharmacologist and the director of research for the NIMH Addiction Research Center at the Public Health Service Hospital in Lexington, Kentucky from 1945 to 1963. He did extensive research on the physical and psychological effects of various drugs on humans. Early work investigated aspects of physical dependence with opiates and barbiturates, while later work investigated psychedelic drugs, including LSD. The research was extensively reported in academic journals such as the Journal of Pharmacology and Experimental Therapeutics, Psychopharmacologia, and the AMA Archives of Neurology and Psychiatry.

<span class="mw-page-title-main">Psilocybin therapy</span> Experimental use of psilocybin to treat anxiety & depression

Psilocybin therapy is the use of psilocybin in treating a range of mental health conditions, such as depression, anxiety, addictions, obsessive compulsive disorder, and psychosis. It is one of several forms of psychedelic therapy under study. Psilocybin was popularized as a psychedelic recreational drug in the 1970s and was classified as a Schedule I drug by the DEA. Research on psilocybin as a medical treatment was restricted until the 1990s because of the sociocultural fear of dependence on this drug. As of 2022, psilocybin is the most commonly researched psychedelic due to its safety and low potential for abuse and dependence. Clinical trials are being conducted at universities and there is evidence confirming the use of psilocybin in the treatment of depression, PTSD and end of life anxiety.

<span class="mw-page-title-main">Post-traumatic stress disorder and substance use disorders</span> Association of PTSD and substance dependencies

Post-traumatic stress disorder (PTSD) can affect about 3.6% of the U.S. population each year, and 6.8% of the U.S. population over a lifetime. 8.4% of people in the U.S. are diagnosed with substance use disorders (SUD). Of those with a diagnosis of PTSD, a co-occurring, or comorbid diagnosis of a SUD is present in 20–35% of that clinical population.

MDMA-assisted psychotherapy is the use of prescribed doses of MDMA as an adjunct to psychotherapy sessions. Research suggests that MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD), including Complex PTSD, might improve treatment effectiveness. In 2017, a Phase II clinical trial led to "breakthrough therapy" designation by the US Food and Drug Administration (FDA) for potential use as a treatment for PTSD.

<span class="mw-page-title-main">MindMed</span> Psychedelic medicine biotech company

Mind Medicine Inc., also known as MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines known as psychoplastogens and therapies to address addiction and mental illness.

Psychoplastogens are a group of small molecule drugs that produce rapid and sustained effects on neuronal structure and function, intended to manifest therapeutic benefit after a single administration. Several existing psychoplastogens have been identified and their therapeutic effects demonstrated; several are presently at various stages of development as medications including Ketamine, MDMA, Scopolamine, and the serotonergic psychedelics, including LSD, psilocin, DMT, and 5-MeO-DMT. Compounds of this sort are being explored as therapeutics for a variety of brain disorders including depression, addiction, and PTSD. The ability to rapidly promote neuronal changes via mechanisms of neuroplasticity was recently discovered as the common therapeutic activity and mechanism of action.

Psychedelic treatments for trauma-related disorders are the use of psychedelic substances, either alone or used in conjunction with psychotherapy, to treat trauma-related disorders. Trauma-related disorders, such as post-traumatic stress disorder (PTSD), have a lifetime prevalence of around 8% in the US population. However, even though trauma-related disorders can hinder the everyday life of individuals with them, less than 50% of patients who meet criteria for PTSD diagnosis receive proper treatment. Psychotherapy is an effective treatment for trauma-related disorders. A meta-analysis of treatment outcomes has shown that 67% of patients who completed treatment for PTSD no longer met diagnostic criteria for PTSD. For those seeking evidence-based psychotherapy treatment, it is estimated that 22-24% will drop out of their treatment. In addition to psychotherapy, pharmacotherapy (medication) is an option for treating PTSD; however, research has found that pharmacotherapy is only effective for about 59% of patients. Although both forms of treatment are effective for many patients, high dropout rates of psychotherapy and treatment-resistant forms of PTSD have led to increased research in other possible forms of treatment. One such form is the use of psychedelics.

References

  1. ↑ "What Does "California Sober" Mean?". Dictionary.com. 2022-08-16. Retrieved 2023-12-29.
  2. ↑ Payan, Madison (2023-11-13). "What is California Sober?". Renaissance Recovery. Retrieved 2023-12-29.
  3. ↑ Gomez, Suzette (2021-08-10). "What Does It Mean To Be "California Sober?"". Addiction Center. Retrieved 2023-12-29.
  4. ↑ Simmons, W. E. (2022). California Sober - The Science of Recovery (1 ed.). SVDC InDUSTries. pp. 1–282. ISBN   9798218319472.
  5. ↑ Lhooq, Michelle (2019-04-29). "Getting 'California Sober' Showed Me a Kinder, Gentler Way to Do Drugs". Vice. Retrieved 2024-02-02.
  6. ↑ Edmonds, Lauren. "Demi Lovato said she identifies as 'California sober' and still consumes alcohol and marijuana in 'moderation'". Insider. Retrieved 2023-12-29.
  7. ↑ Freeman, Jon (2023-04-28). "Billy Strings and Willie Nelson Tout the Benefits of Being 'California Sober' in New Collab". Rolling Stone. Retrieved 2023-12-29.
  8. ↑ Simmons, W. E. (2022). California Sober - The Science of Recovery. SVDC InDUSTries. pp. 1–282. ISBN   9798218319472.
  9. ↑ "What Does "California Sober" Mean?". Dictionary.com. 2022-08-16. Retrieved 2023-12-30.
  10. ↑ Simmons, W. E. (2022). California Sober - The Science of Recovery (1 ed.). SVDC InDUSTries (published January 12, 2022). ISBN   9798218319472.
  11. ↑ Simmons, W. E. (2022). California Sober - The Science of Recovery (1 ed.). SVDC InDUSTries. ISBN   9798218319472.
  12. ↑ Krebs, T. S.; Johansen, P. O. (2012), "Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials", Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet], vol. 26, no. 7, Centre for Reviews and Dissemination (UK), pp. 994–1002, doi:10.1177/0269881112439253, PMID   22406913, S2CID   10677273 , retrieved 2024-01-09
  13. ↑ Bogenschutz, Michael P.; Ross, Stephen; Bhatt, Snehal; Baron, Tara; Forcehimes, Alyssa A.; Laska, Eugene; Mennenga, Sarah E.; O'Donnell, Kelley; Owens, Lindsey T.; Podrebarac, Samantha; Rotrosen, John; Tonigan, J. Scott; Worth, Lindsay (October 2022). "Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder - A Randomized Clinical Trial". JAMA Psychiatry. 79 (10): 953–962. doi:10.1001/jamapsychiatry.2022.2096. PMC   9403854 . PMID   36001306 . Retrieved 2024-01-09.
  14. ↑ Simmons, W.E. (2022). California Sober - The Science of Recovery (1 ed.). SVDC InDUSTries. ISBN   9798218319472.
  15. ↑ Bogenschutz, Michael P.; Ross, Stephen; Bhatt, Snehal; Baron, Tara; Forcehimes, Alyssa A.; Laska, Eugene; Mennenga, Sarah E.; O'Donnell, Kelley; Owens, Lindsey T.; Podrebarac, Samantha; Rotrosen, John; Tonigan, J. Scott; Worth, Lindsay (2022-10-01). "Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial". JAMA Psychiatry. 79 (10): 953–962. doi:10.1001/jamapsychiatry.2022.2096. ISSN   2168-622X. PMC   9403854 . PMID   36001306.
  16. ↑ Frood, Arran (2012-03-09). "LSD helps to treat alcoholism". Nature. doi:10.1038/nature.2012.10200. ISSN   1476-4687. S2CID   137367650.
  17. ↑ O'Leary, Karen (2022-09-08). "Psilocybin therapy reduces heavy drinking". Nature Medicine. doi:10.1038/d41591-022-00093-1. PMID   36076081. S2CID   252161552.
  18. ↑ Meinhardt, Marcus W.; Pfarr, Simone; Fouquet, Grégory; Rohleder, Cathrin; Meinhardt, Manuela L.; Barroso-Flores, Janet; Hoffmann, Rebecca; Jeanblanc, Jérôme; Paul, Elisabeth; Wagner, Konstantin; Hansson, Anita C.; Köhr, Georg; Meier, Nils; von Bohlen und Halbach, Oliver; Bell, Richard L.; Endepols, Heike; Neumaier, Bernd; Schönig, Kai; Bartsch, Dusan; Naassila, Mickaël; Spanagel, Rainer; Sommer, Wolfgang H. (2021). "Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism". Science Advances. 7 (47): eabh2399. Bibcode:2021SciA....7.2399M. doi:10.1126/sciadv.abh2399. hdl:1805/32105. PMC   8598005 . PMID   34788104.
  19. ↑ Krebs, T. S.; Johansen, P. O. (2012), "Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials", Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet], vol. 26, no. 7, Centre for Reviews and Dissemination (UK), pp. 994–1002, doi:10.1177/0269881112439253, PMID   22406913, S2CID   10677273 , retrieved 2024-01-09
  20. ↑ Jones, Grant; Ricard, Jocelyn A.; Lipson, Joshua; Nock, Matthew K. (2022-04-07). "Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample". Scientific Reports. 12 (1): 4099. Bibcode:2022NatSR..12.4099J. doi:10.1038/s41598-022-08085-4. ISSN   2045-2322. PMC   8990065 . PMID   35393455.
  21. ↑ Argento, Elena; Socias, M. Eugenia; Hayashi, Kanna; Choi, JinCheol; Mackay, Lindsay; Christie, Devon; Milloy, M.-J.; DeBeck, Kora (February 2022). "Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting". The International Journal on Drug Policy. 100: 103518. doi:10.1016/j.drugpo.2021.103518. ISSN   1873-4758. PMC   8890776 . PMID   34758431.
  22. ↑ Jones, Grant M.; Nock, Matthew K. (2022-02-16). "Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study". Scientific Reports. 12 (1): 2574. Bibcode:2022NatSR..12.2574J. doi:10.1038/s41598-022-06580-2. ISSN   2045-2322. PMC   8850431 . PMID   35173246.
  23. ↑ Jones, Grant; Lipson, Joshua; Nock, Matthew K. (2022-06-22). "Associations between classic psychedelics and nicotine dependence in a nationally representative sample". Scientific Reports. 12 (1): 10578. Bibcode:2022NatSR..1210578J. doi:10.1038/s41598-022-14809-3. ISSN   2045-2322. PMC   9216303 . PMID   35732796.
  24. ↑ Johnson, Matthew W.; Garcia-Romeu, Albert; Cosimano, Mary P.; Griffiths, Roland R. (November 2014). "Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction". Journal of Psychopharmacology. 28 (11): 983–992. doi:10.1177/0269881114548296. ISSN   0269-8811. PMC   4286320 . PMID   25213996.
  25. ↑ Krebs, Teri S.; Johansen, Pål-Ørjan (July 2012). "Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials". Journal of Psychopharmacology. 26 (7): 994–1002. doi:10.1177/0269881112439253. ISSN   1461-7285. PMID   22406913. S2CID   10677273.
  26. ↑ "APA PsycNet". psycnet.apa.org. Retrieved 2024-01-19.
  27. ↑ Costello, C. G. (February 1969). "An evaluation of aversion and LSD therapy in the treatment of alcoholism". Canadian Psychiatric Association Journal. 14 (1): 31–42. doi:10.1177/070674376901400107. ISSN   0008-4824. PMID   4888140.
  28. ↑ Jensen, S.E.; Ramsay, Ronald (June 1963). "Treatment of Chronic Alcoholism with Lysergic Acid Diethylamide". Canadian Psychiatric Association Journal. 8 (3): 182–188. doi:10.1177/070674376300800305. ISSN   0008-4824. PMID   13957649.
  29. ↑ Abramson, Harold A. (1967). The Use of LSD in Psychotherapy and Alcoholism. Indianapolis New York Kansas City: THE BOBBS-MERRILL COMPANY.
  30. ↑ Gasser, Peter; Holstein, Dominique; Michel, Yvonne; Doblin, Rick; Yazar-Klosinski, Berra; Passie, Torsten; Brenneisen, Rudolf (July 2014). "Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases". The Journal of Nervous and Mental Disease. 202 (7): 513–520. doi:10.1097/NMD.0000000000000113. ISSN   1539-736X. PMC   4086777 . PMID   24594678.
  31. ↑ Moreno, Francisco A.; Wiegand, Christopher B.; Taitano, E. Keolani; Delgado, Pedro L. (November 2006). "Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder". The Journal of Clinical Psychiatry. 67 (11): 1735–1740. doi:10.4088/jcp.v67n1110. ISSN   1555-2101. PMID   17196053.
  32. ↑ Grob, Charles S.; Danforth, Alicia L.; Chopra, Gurpreet S.; Hagerty, Marycie; McKay, Charles R.; Halberstadt, Adam L.; Greer, George R. (January 2011). "Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer". Archives of General Psychiatry. 68 (1): 71–78. doi:10.1001/archgenpsychiatry.2010.116. ISSN   1538-3636. PMID   20819978.
  33. ↑ Johnson, Matthew W.; Garcia-Romeu, Albert; Cosimano, Mary P.; Griffiths, Roland R. (November 2014). "Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction". Journal of Psychopharmacology. 28 (11): 983–992. doi:10.1177/0269881114548296. ISSN   1461-7285. PMC   4286320 . PMID   25213996.
  34. ↑ Jones, Grant; Lipson, Joshua; Nock, Matthew K. (2022-06-22). "Associations between classic psychedelics and nicotine dependence in a nationally representative sample". Scientific Reports. 12 (1): 10578. Bibcode:2022NatSR..1210578J. doi:10.1038/s41598-022-14809-3. ISSN   2045-2322. PMC   9216303 . PMID   35732796.
  35. ↑ Carhart-Harris, R. L.; Bolstridge, M.; Day, C. M. J.; Rucker, J.; Watts, R.; Erritzoe, D. E.; Kaelen, M.; Giribaldi, B.; Bloomfield, M.; Pilling, S.; Rickard, J. A.; Forbes, B.; Feilding, A.; Taylor, D.; Curran, H. V. (February 2018). "Psilocybin with psychological support for treatment-resistant depression: six-month follow-up". Psychopharmacology. 235 (2): 399–408. doi:10.1007/s00213-017-4771-x. ISSN   1432-2072. PMC   5813086 . PMID   29119217.
  36. ↑ Ross, Stephen; Bossis, Anthony; Guss, Jeffrey; Agin-Liebes, Gabrielle; Malone, Tara; Cohen, Barry; Mennenga, Sarah E.; Belser, Alexander; Kalliontzi, Krystallia; Babb, James; Su, Zhe; Corby, Patricia; Schmidt, Brian L. (December 2016). "Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial". Journal of Psychopharmacology. 30 (12): 1165–1180. doi:10.1177/0269881116675512. ISSN   1461-7285. PMC   5367551 . PMID   27909164.
  37. ↑ Griffiths, Roland R.; Johnson, Matthew W.; Carducci, Michael A.; Umbricht, Annie; Richards, William A.; Richards, Brian D.; Cosimano, Mary P.; Klinedinst, Margaret A. (December 2016). "Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial". Journal of Psychopharmacology. 30 (12): 1181–1197. doi:10.1177/0269881116675513. ISSN   1461-7285. PMC   5367557 . PMID   27909165.
  38. ↑ Bogenschutz, Michael P.; Ross, Stephen; Bhatt, Snehal; Baron, Tara; Forcehimes, Alyssa A.; Laska, Eugene; Mennenga, Sarah E.; O'Donnell, Kelley; Owens, Lindsey T.; Podrebarac, Samantha; Rotrosen, John; Tonigan, J. Scott; Worth, Lindsay (2022-10-01). "Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial". JAMA Psychiatry. 79 (10): 953–962. doi:10.1001/jamapsychiatry.2022.2096. ISSN   2168-622X. PMC   9403854 . PMID   36001306.
  39. ↑ Argento, Elena; Socias, M. Eugenia; Hayashi, Kanna; Choi, JinCheol; Mackay, Lindsay; Christie, Devon; Milloy, M.-J.; DeBeck, Kora (February 2022). "Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting". The International Journal on Drug Policy. 100: 103518. doi:10.1016/j.drugpo.2021.103518. ISSN   1873-4758. PMC   8890776 . PMID   34758431.
  40. ↑ Jones, Grant; Ricard, Jocelyn A.; Lipson, Joshua; Nock, Matthew K. (2022-04-07). "Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample". Scientific Reports. 12 (1): 4099. Bibcode:2022NatSR..12.4099J. doi:10.1038/s41598-022-08085-4. ISSN   2045-2322. PMC   8990065 . PMID   35393455.
  41. ↑ "Curing Drug and Alcohol Addiction with Peyote". Discover Magazine. Retrieved 2024-01-19.
  42. ↑ Jones, Grant M.; Nock, Matthew K. (2022-02-16). "Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study". Scientific Reports. 12 (1): 2574. Bibcode:2022NatSR..12.2574J. doi:10.1038/s41598-022-06580-2. ISSN   2045-2322. PMC   8850431 . PMID   35173246.
  43. ↑ Jones, Grant; Lipson, Joshua; Nock, Matthew K. (2022-06-22). "Associations between classic psychedelics and nicotine dependence in a nationally representative sample". Scientific Reports. 12 (1): 10578. Bibcode:2022NatSR..1210578J. doi:10.1038/s41598-022-14809-3. ISSN   2045-2322. PMC   9216303 . PMID   35732796.
  44. ↑ Karoly, Hollis C.; Ross, J. Megan; Prince, Mark A.; Zabelski, Alexandra E.; Hutchison, Kent E. (September 2021). "Effects of cannabis use on alcohol consumption in a sample of treatment-engaged heavy drinkers in Colorado". Addiction. 116 (9): 2529–2537. doi:10.1111/add.15407. ISSN   1360-0443. PMC   8286984 . PMID   33464670.
  45. ↑ Lucas, Philippe; Boyd, Susan; Milloy, M.-J.; Walsh, Zach (2020-10-15). "Reductions in alcohol use following medical cannabis initiation: results from a large cross-sectional survey of medical cannabis patients in Canada". The International Journal on Drug Policy. 86: 102963. doi:10.1016/j.drugpo.2020.102963. ISSN   1873-4758. PMID   33068830. S2CID   224321211.
  46. ↑ "APA PsycNet". psycnet.apa.org. Retrieved 2024-01-20.
  47. ↑ Lopez-Quintero, Catalina; Pérez de los Cobos, José; Hasin, Deborah S.; Okuda, Mayumi; Wang, Shuai; Grant, Bridget F.; Blanco, Carlos (2011-05-01). "Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)". Drug and Alcohol Dependence. 115 (1–2): 120–130. doi:10.1016/j.drugalcdep.2010.11.004. ISSN   1879-0046. PMC   3069146 . PMID   21145178.
  48. ↑ Budney, A. J.; Roffman, R.; Stephens, R. S.; Walker, D. (2007). "Marijuana Dependence and Its Treatment". Addiction Science & Clinical Practice. 4 (1): 4–16. doi:10.1151/ascp07414. PMC   2797098 . PMID   18292704.
  49. ↑ Bonomo, Y. (2005). "Cannabis Use and Dependence: Public Health and Public Policy, Young People and Substance Abuse". BMJ : British Medical Journal. 330 (7481): 49. doi:10.1136/bmj.330.7481.49. PMC   539863 .
  50. ↑ Garland, Eric L.; Hanley, Adam W.; Nakamura, Yoshio; Barrett, John W.; Baker, Anne K.; Reese, Sarah E.; Riquino, Michael R.; Froeliger, Brett; Donaldson, Gary W. (2022-04-01). "Mindfulness-Oriented Recovery Enhancement vs Supportive Group Therapy for Co-occurring Opioid Misuse and Chronic Pain in Primary Care: A Randomized Clinical Trial". JAMA Internal Medicine. 182 (4): 407–417. doi:10.1001/jamainternmed.2022.0033. ISSN   2168-6106. PMC   8886485 . PMID   35226053.
  51. ↑ Gryczynski, Jan; Schwartz, Robert P.; Fishman, Marc J.; Nordeck, Courtney D.; Grant, James; Nidich, Sanford; Rothenberg, Stuart; O'Grady, Kevin E. (April 2018). "Integration of Transcendental Meditation® (TM) into alcohol use disorder (AUD) treatment". Journal of Substance Abuse Treatment. 87: 23–30. doi:10.1016/j.jsat.2018.01.009. ISSN   1873-6483. PMID   29471923.
  52. ↑ Balban, Melis Yilmaz; Neri, Eric; Kogon, Manuela M.; Weed, Lara; Nouriani, Bita; Jo, Booil; Holl, Gary; Zeitzer, Jamie M.; Spiegel, David; Huberman, Andrew D. (2023-01-17). "Brief structured respiration practices enhance mood and reduce physiological arousal". Cell Reports. Medicine. 4 (1): 100895. doi:10.1016/j.xcrm.2022.100895. ISSN   2666-3791. PMC   9873947 . PMID   36630953.
  53. ↑ Smith, Mark A.; Lynch, Wendy J. (2011). "Exercise as a potential treatment for drug abuse: evidence from preclinical studies". Frontiers in Psychiatry. 2: 82. doi: 10.3389/fpsyt.2011.00082 . ISSN   1664-0640. PMC   3276339 . PMID   22347866.
  54. ↑ Smith, Mark (2018-04-02). "Resistance exercise decreases heroin self-administration and alters gene expression in the nucleus accumbens of heroin-exposed rats". Psychopharmacology. 235 (4): 1245–1255. doi:10.1007/s00213-018-4840-9. PMC   5871570 . PMID   29396617.
  55. ↑ "APA PsycNet". psycnet.apa.org. Retrieved 2024-01-28.
  56. ↑ Streeter, Chris C.; Whitfield, Theodore H.; Owen, Liz; Rein, Tasha; Karri, Surya K.; Yakhkind, Aleksandra; Perlmutter, Ruth; Prescot, Andrew; Renshaw, Perry F.; Ciraulo, Domenic A.; Jensen, J. Eric (November 2010). "Effects of yoga versus walking on mood, anxiety, and brain GABA levels: a randomized controlled MRS study". Journal of Alternative and Complementary Medicine. 16 (11): 1145–1152. doi:10.1089/acm.2010.0007. ISSN   1557-7708. PMC   3111147 . PMID   20722471.
  57. ↑ Willman, Chris (April 27, 2023). "Billy Strings and Willie Nelson Commit to Going 'California Sober' in Duet Released for Willie's Birthday". Variety . Retrieved June 12, 2023.
  58. ↑ "In Popular Culture". IMDb .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.